Eli Lilly & Co (LLY) Earnings Date & Reports
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology... Show more
LLY is expected to report earnings to rise 3.04% to $8.81 per share on August 05
Eli Lilly (LLY) Q1 2026 Earnings Recap: Mounjaro, Zepbound Fuel 56% Revenue Surge
Key Takeaways
- Eli Lilly reported Q1 2026 worldwide revenue of $19.8 billion, a 56% increase from $12.7 billion in the prior-year quarter, beating consensus estimates around $17.5-17.8 billion.
- Non-GAAP earnings per share (EPS) reached $8.55, up 156% year-over-year and exceeding analyst expectations of $7.26.
- Mounjaro generated $8.7 billion in sales, up 125%, while Zepbound contributed $4.2 billion, up 80%.
- Company raised full-year 2026 revenue guidance to $82-85 billion (from $80-83 billion) and non-GAAP EPS to $35.50-37.00 (from $33.50-35.00).
- Gross margin stood at 81.9% of revenue, slightly down due to lower realized prices on incretin therapies.
- Pipeline advances included U.S. FDA approval of Foundayo, the first oral GLP-1 (glucagon-like peptide-1) therapy for obesity.
Earnings Context and Why It Matters
Eli Lilly's Q1 2026 earnings are pivotal amid its leadership in the GLP-1 drug market for diabetes and obesity treatment. The company has seen explosive growth from Mounjaro and Zepbound, but faces pricing pressures, manufacturing constraints, and competition from Novo Nordisk. Investors closely watch these results for signs of sustained demand, margin resilience, and pipeline momentum, as they signal Eli Lilly's ability to maintain market dominance and fund R&D (research and development) in immunology, oncology, and neuroscience. Strong execution here reinforces confidence in long-term growth prospects in a high-stakes therapeutic sector.
Eli Lilly delivered standout Q1 2026 results. Worldwide revenue climbed 56% to $19.8 billion, driven by 65% volume growth from incretin products Mounjaro and Zepbound, partially offset by 13% lower realized prices. U.S. revenue rose 43% to $12.1 billion, while ex-U.S. surged 81% to $7.7 billion, boosted by Mounjaro's inclusion on China's NRDL (National Reimbursement Drug List).
Non-GAAP EPS soared 156% to $8.55, well above the $7.26 consensus, with reported EPS at $8.26. Key products like Mounjaro ($8.7 billion, +125%) and Zepbound ($4.2 billion, +80%) led the charge, alongside gains in Jaypirca (+79%) and Ebglyss (+141%). Gross margin dipped slightly to 81.9% from pricing impacts, while R&D expenses rose 28% to $3.5 billion, reflecting pipeline investments.
Guidance was raised meaningfully: full-year revenue now $82-85 billion and non-GAAP EPS $35.50-37.00, signaling confidence in volume momentum despite headwinds.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your stock analysis workflow.
Market Reaction and Investor Sentiment
Following the Q1 beat and upbeat guidance, Eli Lilly shares soared in after-hours trading, reflecting investor enthusiasm for the robust incretin demand and raised outlook. Sentiment turned strongly positive, with focus on the company's execution amid GLP-1 competition, though some noted ongoing pricing and rebate pressures.
Forward Outlook and Key Factors to Monitor
Investors should track Eli Lilly's progress toward its elevated 2026 guidance, particularly volume growth in Mounjaro and Zepbound amid sustained obesity treatment demand. Pricing dynamics, including U.S. rebates and international reimbursement changes like China's NRDL, will influence margins.
Manufacturing capacity remains critical, as supply constraints have historically limited sales. Pipeline catalysts include Phase 3 readouts for retatrutide, Jaypirca expansions, and combinations like Taltz plus Zepbound. The recent FDA approval of Foundayo positions Eli Lilly to capture more patients with an oral GLP-1 option, potentially broadening market access.
Acquisitions such as Orna, Centessa, and others signal R&D diversification into cell therapies and rare diseases. Broader factors like IPR&D (acquired in-process research and development) charges and litigation costs bear watching. Overall, balanced execution on these fronts will shape trajectory in a competitive pharma landscape.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry PharmaceuticalsMajor